Amicus Therapeutics, Inc. (NASDAQ:FOLD) is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, FOLD to report 2Q20 loss of $ 0.26 per share from revenue of $ 62.38 million.
For the full year, analysts anticipate top line of $ 254.82 million, while looking forward to loss of $ 1.07 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 250.00 million ~ $ 260.00 million
Click Here For More Historical Outlooks Of Amicus Therapeutics, Inc.
Previous Quarter Performance
Amicus Therapeutics, Inc. unfold loss for the first quarter of $ 0.35 per share, from the revenue of $ 60.52 million. The quarterly revenues extended 59.85 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.28 per share from $ 57.49 million in revenue. The bottom line results missed street analysts by $ 0.07 or 25 percent, at the same time, top line results outshined analysts by $ 3.03 million or 5.27 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Amicus Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of FOLD was $ 15.41, representing a 146.56 % increase from the 52 week low of $ 6.25 and a 4.46 % decrease over the 52 week high of $ 16.13.
The company has a market capital of $ 3.97 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”FOLD” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Amicus Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.amicusrx.com
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
